Last year proved a tough pill to swallow for biotech stocks. According to SmartMoney’s Sector Tracker, they’ve collectively dropped nearly 7% over the past 52 weeks. Among those hit the hardest, Amgen (Nasdaq: AMGN) and Nektar Therapeutics (Nasdaq: NKTR) each endured a blood loss of more than 20%.>>> Discuss This Story
